HK Stock Market Move | ABBISSCO-B(02256)up over 7% during trading, showcasing Phase III clinical trial data for Pimetinib at the 2025 ESMO conference.

ABBISKO-B rose more than 7% during intraday trading, and as of the time of writing, it was up 6.06% to 15.03 Hong Kong dollars, with a trading volume of 9.1686 million Hong Kong dollars. On the news front, ABBISKO-B recently announced that its subsidiary Shanghai Heyu Biotechnology Co., Ltd. (Heyu Medicine) presented the long-term efficacy and safety data of its global Phase III MANEUVER study on the treatment of tenosynovial giant cell tumor (TGCT) patients with pimicotinib (pimicotinib/ABSK021) in the form of an oral presentation at the 2025 European Society for Medical Oncology Annual Conference (2025 ESMO Conference). Currently, pimicotinib has been granted priority review by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for use in adult TGCT patients requiring systemic treatment. Pimicotinib has also been granted breakthrough therapy designation (BTD) by the NMPA. In overseas markets, pimicotinib has received BTD from the U.S. Food and Drug Administration (FDA) and has been granted PRIME (Priority Medicine) designation by the European Medicines Agency (EMA).